Pharmacokinetics of levofloxacin in patients with pneumonia
Abstract
Objective: To study the pharmacokinetics of intravenous levofloxacin in patients with pulmonary infection.Methods: Levofloxacin concentration in serum were determinated by HPLC and the pharmaceutical parameters of levofloxacin were calculated.Results: The linear range was 0.8～6.4 mg/L(r=0.999 2).AUC0→12,t1/2 and ke of levofloxacin were(17.35±1.84) mg.h/L,(6.102±0.416 3)h 和(0.114 1±0.008 2) h-1,respectively.Conclusion: The serum concentration and AUC of levofloxacin in patients with pulmonary infection are smaller than that in healthy subjects.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.